ALX ONCOLOGY HOLDINGS INC
ALX ONCOLOGY HOLDINGS INC
Aktie · US00166B1052 · ALXO (XNAS)
Übersicht Finanzkennzahlen
0,59 USD
13,03 % 0,07 USD
NASDAQ (XNAS) · Aktuelle Kurse und Charts bei MoneyPeak
06.06.2025 23:15

Aktuelle Kurse von ALX ONCOLOGY HOLDINGS INC

BörseTickerWährungLetzter UmsatzKursTagesveränderung
XNAS: NASDAQ
NASDAQ
ALXO
USD
06.06.2025 23:15
0,59 USD
0,52 USD
+12,51 %

Performance

Heute Woche Monat 3 Monate 6 Monate 1 Jahr 5 Jahre
0,00 % 18,00 % 16,62 % -53,91 % -63,58 % -93,64 % -98,03 %

Firmenprofil zu ALX ONCOLOGY HOLDINGS INC Aktie

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors. The company's pre-clinical products include ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was founded in 2015 and is headquartered in South San Francisco, California.

Investierte Fonds

Folgende Fonds haben in investiert: ALX ONCOLOGY HOLDINGS INC investiert:

Fonds
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Vol. in Mio
93,69
Anteil (%)
0,22 %

Unternehmensdaten

Name ALX ONCOLOGY HOLDINGS INC
Firma ALX Oncology Holdings Inc.
Symbol ALXO
Website https://www.alxoncology.com
Heimatbörse XNAS NASDAQ
ISIN US00166B1052
Wertpapierart Aktie
Sektor Healthcare
Branche Biotechnology
CEO Mr. Jason W. Lettmann
Marktkapitalisierung 30 Mio
Land Vereinigte Staaten von Amerika
Währung USD
Mitarbeiter 0,1 T
Adresse 323 Allerton Avenue, 94080 South San Francisco
IPO Datum 2020-07-17

Ticker Symbole

Name Symbol
NASDAQ ALXO

Weitere Aktien

Investoren die ALX ONCOLOGY HOLDINGS INC die halten, haben auch folgende Aktien im Depot:
CABASSE S.A.      EO -,50
CABASSE S.A. EO -,50 Aktie
NETLease Corporate Real Estate ETF
NETLease Corporate Real Estate ETF ETF
Die Finanzplattform MoneyPeak trackt und analysiert Investitionen und Portfolios. Vom Wertpapier-Depot bis zum Crypto-Kauf.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
Impressum Datenschutz Blog Community Feedback Changelog
Im App Store herunterladen Bei Google Play herunterladen
All rights reserved © LCP GmbH 2025